CAD 0.87
(-4.4%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 | - USD | 0.0% |
2023 | - USD | 0.0% |
2022 | - USD | -100.0% |
2021 | 25.98 Thousand USD | -88.64% |
2020 | 228.74 Thousand CAD | -24.09% |
2019 | 301.32 Thousand CAD | -73.11% |
2018 | 1.12 Million CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2024 Q3 | - USD | 0.0% |
2024 Q4 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2022 Q2 | - USD | -100.0% |
2022 Q1 | 26.96 Thousand USD | 3.76% |
2022 FY | - USD | -100.0% |
2022 Q4 | - USD | 0.0% |
2021 Q2 | 386.55 Thousand CAD | 49.39% |
2021 FY | 25.98 Thousand USD | -88.64% |
2021 Q1 | 258.75 Thousand CAD | 13.12% |
2021 Q4 | 25.98 Thousand USD | 0.0% |
2021 Q3 | - CAD | -100.0% |
2020 Q2 | 150.62 Thousand CAD | 0.0% |
2020 Q4 | 228.74 Thousand CAD | 6.64% |
2020 FY | 228.74 Thousand CAD | -24.09% |
2020 Q1 | - CAD | -100.0% |
2020 Q3 | 214.49 Thousand CAD | 42.41% |
2019 Q3 | 311.47 Thousand CAD | -36.61% |
2019 Q1 | 825.41 Thousand CAD | -26.35% |
2019 FY | 301.32 Thousand CAD | -73.11% |
2019 Q4 | 301.32 Thousand CAD | -3.26% |
2019 Q2 | 491.34 Thousand CAD | -40.47% |
2018 Q3 | 979.71 Thousand CAD | 0.0% |
2018 FY | 1.12 Million CAD | 0.0% |
2018 Q4 | 1.12 Million CAD | 14.39% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Appili Therapeutics Inc. | 8.18 Million CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | 13.78 Million CAD | 100.0% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 6.64 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | - CAD | NaN% |
Oncolytics Biotech Inc. | 423 Thousand CAD | 100.0% |
Sernova Corp. | 136.12 Thousand CAD | 100.0% |